of stroke. In agreement with this caveat, we note that PDE4D genotypes or haplotypes do not influence the risk of peripheral artery occlusive disease or coronary artery disease (see Supplementary Table 7 from ref. 1), although atherosclerosis is the cause of both disorders in more than 90% of cases.
The genetic analysis of the whole group of individuals with ischemic stroke showed a possible though nonsignificant association of anonymous markers at the PDE4D locus with stroke. In this context, the additional finding of downregulation of several PDE4D mRNA isoforms in individuals with ischemic stroke further suggests that PDE4D is a very good candidate for genetic modulation of ischemic stroke risk. Gretarsdottir et al. only considered the possible involvement of PDE4D in atherogenesis, which is supported by few experimental data 1 . By contrast, phosphodiesterase 4 has repeatedly been reported to be involved in susceptibility to ischemic brain damage in animal models [5] [6] [7] [8] . Such a mechanism directly related to cerebral ischemia could explain why the PDE4D locus was found to be in linkage with stroke regardless of cause in the Icelandic population 2 .
It seems that the PDE4D functional variant that influences the risk of ischemic stroke has yet to be identified, as statistically significant associations were found only in a pathophysiologically inadequate subgroup of individuals in the present study. Genotyping studies are becoming more comprehensive and including growing numbers of polymorphisms in each study. Accurate phenotype definition seems more than ever to be a necessary prerequisite to establish reliable genotype-phenotype relationships in the study of complex disorders. 
In reply
Definitions of clinical phenotypes are often arrived at through consensus criteria that may have little to do with the underlying biology. Stroke is an entity with subtypes that lack clear biological correlates.
Funalot et al. argue that there is a methodological problem in our genetic association study, namely, our combined analyses of the carotid and cardiogenic stroke subtypes. They do not agree that atherosclerosis is the primary pathological process for both carotid and cardiogenic stroke and claim that only 25% of cardiogenic strokes result directly from coronary atherosclerosis and 65% are due to valvular heart disease or atrial fibrillation (<20% of those being attributable to coronary atherosclerosis). This is a different pattern from that seen in our Icelandic stroke cohort, in which at least 47% of individuals with cardiogenic stroke have coronary artery disease. Atrial fibrillation is observed in 79% of individuals with cardiogenic stroke, and 44% of those have documented coronary artery disease. Recent studies, especially in Scandinavian populations, of atrial fibrillation show that
